Literature DB >> 29477302

Adherence to colorectal cancer screening measured as the proportion of time covered.

Caitlin C Murphy1, Bianca M Sigel2, Edward Yang3, Celette Sugg Skinner1, Ethan A Halm4, Samir Gupta5, Joanne M Sanders2, Katharine McCallister2, Amit G Singal4.   

Abstract

BACKGROUND AND AIMS: Colorectal cancer (CRC) screening can reduce CRC incidence and mortality, but measuring screening adherence over time is challenging. We examined adherence using a novel measure characterizing the proportion of time covered (PTC) by screening tests.
METHODS: Eligible patients were age 50 to 60 years and followed at a large, safety-net health care system between January 2010 and September 2014. We estimated PTC as the number of days up to date with screening divided by the number of days from cohort entry until study end, CRC diagnosis, or death. We estimated mean and median PTC and used least-significant difference tests to assess differences in adherence by patient characteristics.
RESULTS: Of 18,257 patients, most were non-Hispanic black (40.5%) or Hispanic (34.9%) and/or female (62.4%). Approximately 40% (n = 7559) were never screened during the study period; the remaining 10,698 patients completed 19,105 screening examinations (14,481 fecal immunochemical tests [FITs], 4393 colonoscopies, 94 sigmoidoscopies, and 137 barium enemas). Overall, the mean PTC was 29.1% (95% confidence interval [CI], 28.6%-29.5%). Among those who completed at least one screening test (n = 10,698), the mean PTC was 49.0% (95% CI, 48.5%-49.5%). The most common reasons for non-adherence were lack of repeat FIT and no diagnostic colonoscopy after abnormal results for the FIT. The mean PTC increased with the number of primary care visits (0 visits, 21%; 1 visit, 29%; 2-3 visits, 35%; ≥4 visits, 37%; all P < .05).
CONCLUSIONS: PTC provides a reliable estimate of screening adherence, capturing breakdowns in the CRC screening process amenable to intervention. Repeat FIT and diagnostic colonoscopy are important intervention targets that may increase adherence in underserved populations.
Copyright © 2018 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29477302      PMCID: PMC6050149          DOI: 10.1016/j.gie.2018.02.023

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  52 in total

1.  How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity.

Authors:  Laura C Seeff; Thomas B Richards; Jean A Shapiro; Marion R Nadel; Diane L Manninen; Leslie S Given; Fred B Dong; Linda D Winges; Matthew T McKenna
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

2.  The effect of HEDIS measurement of colorectal cancer screening on insurance plans in Pennsylvania.

Authors:  Mona Sarfaty; Ronald E Myers
Journal:  Am J Manag Care       Date:  2008-05       Impact factor: 2.229

3.  Association Between Primary Care Visits and Colorectal Cancer Screening Outcomes in the Era of Population Health Outreach.

Authors:  Ethan A Halm; Elisabeth F Beaber; Dale McLerran; Jessica Chubak; Douglas A Corley; Carolyn M Rutter; Chyke A Doubeni; Jennifer S Haas; Bijal A Balasubramanian
Journal:  J Gen Intern Med       Date:  2016-06-08       Impact factor: 5.128

4.  Overuse of screening colonoscopy in the Medicare population.

Authors:  James S Goodwin; Amanpal Singh; Nischita Reddy; Taylor S Riall; Yong-Fang Kuo
Journal:  Arch Intern Med       Date:  2011-05-09

Review 5.  Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society.

Authors:  Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex
Journal:  Gastroenterology       Date:  2006-05       Impact factor: 22.682

6.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

7.  Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening.

Authors:  Elisabeth F Beaber; Jane J Kim; Marilyn M Schapira; Anna N A Tosteson; Ann G Zauber; Ann M Geiger; Aruna Kamineni; Donald L Weaver; Jasmin A Tiro
Journal:  J Natl Cancer Inst       Date:  2015-05-07       Impact factor: 13.506

8.  The colorectal cancer screening process in community settings: a conceptual model for the population-based research optimizing screening through personalized regimens consortium.

Authors:  Jasmin A Tiro; Aruna Kamineni; Theodore R Levin; Yingye Zheng; Joanne S Schottinger; Carolyn M Rutter; Douglas A Corley; Celette S Skinner; Jessica Chubak; Chyke A Doubeni; Ethan A Halm; Samir Gupta; Karen J Wernli; Carrie Klabunde
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-10       Impact factor: 4.254

9.  Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial.

Authors:  J D Hardcastle; N C Armitage; J Chamberlain; S S Amar; P D James; T W Balfour
Journal:  Cancer       Date:  1986-07-15       Impact factor: 6.860

10.  Cancer screening test use - United States, 2013.

Authors:  Susan A Sabatino; Mary C White; Trevor D Thompson; Carrie N Klabunde
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-05-08       Impact factor: 17.586

View more
  6 in total

1.  Challenges and Approaches to Measuring Repeat Fecal Immunochemical Test for Colorectal Cancer Screening.

Authors:  Caitlin C Murphy; Ethan A Halm; Celette Sugg Skinner; Bijal A Balasubramanian; Amit G Singal
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-26       Impact factor: 4.254

2.  Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis.

Authors:  Debra T Choi; Hye-Chung Kum; Sulki Park; Robert L Ohsfeldt; Yu Shen; Neehar D Parikh; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-10-26       Impact factor: 11.382

3.  Colorectal Neoplasia among Patients with and without Human Immunodeficiency Virus.

Authors:  Adil Faqih; Amit G Singal; Hannah M Fullington; Benjamin Hewitt; Ezra Burstein; Purva Gopal; Annika Wylie; John Abrams; Caitlin C Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

4.  Methodologic Considerations in Calculating and Analyzing Proportion of Time Covered as a Measure of Longitudinal Cancer Screening Adherence.

Authors:  Jessica Chubak; Melissa L Anderson; Andrea J Cook; Caitlin C Murphy; Michael L Jackson; Beverly B Green
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-05-28       Impact factor: 4.254

5.  Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort.

Authors:  Neehar D Parikh; Nabihah Tayob; Taim Al-Jarrah; Jennifer Kramer; Jennifer Melcher; Donna Smith; Patrick Marquardt; Po-Hong Liu; Runlong Tang; Fasiha Kanwal; Amit G Singal
Journal:  JAMA Netw Open       Date:  2022-07-01

6.  A Centralized Program with Stepped Support Increases Adherence to Colorectal Cancer Screening Over 9 Years: a Randomized Trial.

Authors:  Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon
Journal:  J Gen Intern Med       Date:  2021-05-28       Impact factor: 6.473

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.